 (CEA) 
Pancreatic carcinoma is still a problematic cancer despite the improving imaging methods. We still lack a good method to screen symptomless people and to diagnose cancer early enough for curative treatment. Only about 10% of patients with pancreatic carcinoma are diagnosed early enough for resection, and the 5-year prognosis of these patients with resectable tumour is only 4% or less (Longmire, 1984; Eskelinen et al., 1991) . Therefore, every effort should be made to develop better methods for early diagnosis. At the present time tumour markers seem to be most ideal for this purpose. A variety of tumour markers have been demonstrated to be associated with pancreatic carcinoma, but the sensitivities and specificities of these tumour markers have not yet reached the level for screening an asymptomatic population. The most intensively studied tumour markers in pancreatic cancer are carcinoembryonic antigen (CEA) (Kalser et al., 1978; Hansen et al., 1974; Begent, 1984) , CA 50 (Lindholm et al., 1983; Holmgren et al., 1984; Paganuzzi et al., 1985; Jalanko et al., 1985; Habib et al., 1986a) , and CA 19-9 (Haglund et al., 1986; Kuusela et al., 1991) . CA 242 is a novel tumour associated antigen, which has been suggested as a potential candidate for a serum tumour marker in pancreatic cancer (Haglund et al., 1989; Kuusela et al., 1991) . The aim of this study was to evaluate the diagnostic accuracy of CA 242 in the detection of pancreatic cancer and to compare it with the established serum markers CEA and CA 50. The serum levels from patients with pancreatic cancer were compared with those from patients with benign pancreatic diseases, and with benign and malignant biliary tract and hepatocellular diseases. (Table  II) . When we used the cut-off level of 20 U ml-' for CA 242, four patients with a carcinoma of the biliary tract was above this level. In malignant liver diseases (n = 4), the median serum CA 242 concentration was 8.6 U ml-', and none of them were above the cut-off level of 20 U ml-I (Figure 1 , Table II ).
In the patients with a malignant hepatopancreatico-biliary disease (n = 42), the mean serum CA 242 concentration (887.4 U ml-' was significantly higher (P <0.0001, Wilcoxon's test) than the mean value (59.2 U ml-') of the patients with benign disease (n = 151).
CA 242 in benign hepatopancreatico-biliary diseases Among the benign diseases, the highest values were measured in choledochal stone disease (median 10.8 U ml-', range 5.0-1893.0 U ml-'), and in 26% (13/50) of patients the serum CA 242 value was above the cut-off value of 20 U ml-' (Figure 1 , Table II ). In the patients with a benign liver disease, 20.6% (6/29) of patients had a higher value than 20 U ml-'. In the patients with acute or chronic pancreatitis the respecting values were 33% (2/6) and 14% (5/34) ( Figure 1 , Table II ).
Comparison and combinations of the markers The diagnostic sensitivities of CA 242, CEA and CA 50 were 80.7%, 92.3% and 96.1%, and specificities 79.0%, 59.2% and 58.0%, respectively. The sensitivity, specificity, PV+ and PV-of the combinations of the markers are presented in Table IV .
Discussion
The clinical role of tumour markers in pancreatic cancer is not clearly established. No ideal tumour marker has been yet developed. The lack of specificity is one of the great problems. For example, elevated CA 50 and CEA values are also seen in hepatocellular jaundice, and in benign hepatic and extrahepatic diseases (Jalanko et al., 1985; Bruhn et al., 1985; Habib et al., 1986b, c; Chan et al., 1985; Hansen et al., 1974; Kalser et al., 1978; Carr-Locke, 1980) .
In the present study, the clinical value of a new serum tumour marker CA 242 was evaluated. Monoclonal antibody C 242 was obtained after immunisation of mice with a human colorectal adenocarcinoma cell line . The exact nature of the antigen determinant is not known, but it seems to be a sialylated carbohydrate structure and chemically closely related to CA 19-9 and CA 50 (Haglund et al., 1989) . In our study, the sensitivity of CA 242 was considerably high (80.7%), even though lower than that of CEA or CA 50. On the other hand, the specificity of CA 242 (79.0%) was highest of the three markers. In a study of Haglund et al. (Haglund et al., 1989) a slightly lower (65%) sensitivity was reached than in the present series, but the specificity was not determined. In our study, as well as in the study of Haglund et al. (Haglund et al., 1989 ) the upper limit of normal 20 U ml' was used for the assay as based on serum levels of healthy blood donors (Nilsson et al., 1988) . It has been recommended that the cut-off level should be determined by using the 95th percentile of benign diseases, because it tests best the real clinical value of a tumour marker (Roberts, 1986) . In the present series, by using this criteria, the cut-off value level would have been 63 U ml-. The sensitivity of CA 242 would have been 61.5% and specificity 95.2%. The present patient population is a consecutive series of patients admitted to one university hospital, and a large proportion of these patients had whether jaundice (113/193) or unjaundiced cholestasis (20/193) . From this point of view, our patient material can be well regarded as clinically relevant, and therefore the high specificity of CA 242 must be emphasised.
It has been noticed in many previous studies, that the combinations of these markers give only little further benefit. This was the case also in the present study, since the specificity of CA 242 alone was good, and the sensitivity CA 50 alone was equal to those of the combinations. It is clear that if we require for example, two tests to be positive, we can reach high specificity, but at the cost of sensitivity, and if we require only either of the tests to be positive, we can reach higher sensitivity with rather low specificity. In the light of the present study, the most ideal combination would seem to be a combination of CA 242 and CEA. If we have either of the tests positive, we reach high sensitivity (96.1%) and if both tests are positive, we can reach high (92.2%), too (Table IV) .
It can be concluded, that the sensitivity of CA 242 is lower than that of the older markers CA 50 and CEA in the diagnosis of pancreatic cancer, but it may prove useful because of its higher specificity. The relative insensitivity of CA 242 can be improved by combining it with CEA or CA 50.
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